DOGWOOD THERAPEUTICS INC(DWTX)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

DWTX DOGWOOD THERAPEUTICS INC

交易中 02-24 14:10:06 EST

2.84

+0.09

+3.27%

最高2.89	最低2.75	成交量1.22万
今开2.85	昨收2.75	日振幅5.09%
总市值9,456万	流通市值1,987万	总股本3,330万
成交额3.46万	换手率0.17%	流通股本699.59万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"DWTX","market":"US","secType":"STK","nameCN":"DOGWOOD THERAPEUTICS INC","latestPrice":2.84,"timestamp":1771960109346,"preClose":2.75,"halted":0,"volume":12192,"delay":0,"changeRate":0.032727272727272674,"floatShares":6995900,"shares":33295600,"eps":-24.9248,"marketStatus":"交易中","change":0.09,"latestTime":"02-24 14:10:06 EST","open":2.85,"high":2.89,"low":2.75,"amount":34588.793001599995,"amplitude":0.050909,"askPrice":2.91,"askSize":100,"bidPrice":2.76,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-24.9248,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1771966800000},"marketStatusCode":2,"adr":0,"listingDate":1608181200000,"exchange":"NASDAQ","adjPreClose":2.75,"postHourTrading":{"tag":"盘后","latestPrice":2.8725,"preClose":2.75,"latestTime":"18:19 EST","volume":598,"amount":1690.5919,"timestamp":1771888795923,"change":0.1225,"changeRate":0.044545,"amplitude":0.065455},"volumeRatio":0.904707},"requestUrl":"/m/hq/s/DWTX","defaultTab":"news","newsList":[{"id":"1160646340","title":"Dogwood Therapeutics宣布Halneuron®二期B阶段试验完成50%患者入组，关键数据预计2026年第三季度公布","url":"https://stock-news.laohu8.com/highlight/detail?id=1160646340","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1160646340?lang=zh_cn&edition=full","pubTime":"2026-02-02 21:32","pubTimestamp":1770039150,"startTime":"0","endTime":"0","summary":"生物制药公司Dogwood Therapeutics（股票代码：DWTX）近日披露，其核心候选药物Halneuron®的二期B阶段临床试验已完成半数患者入组。该试验旨在评估药物治疗特定适应症的有效性与安全性，目前进展符合预期时间表。\n公司明确表示，此次试验的关键顶线数据预计将于2026年第三季度正式对外公布。若结果达到临床终点，将为后续申报上市提供重要依据。\n市场对Halneuron®的商业潜力持续关注，该进展被视为公司研发管线推进的重要里程碑。Dogwood Therapeutics强调将严格遵循临床试验规范，确保数据收集的准确性与完整性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DWTX","BK4139"],"gpt_icon":0},{"id":"1164963651","title":"Dogwood Therapeutics计划于2026年底向FDA提交Halneuron二期研究总结、生产计划及三期临床开发方案","url":"https://stock-news.laohu8.com/highlight/detail?id=1164963651","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1164963651?lang=zh_cn&edition=full","pubTime":"2026-01-20 21:39","pubTimestamp":1768916372,"startTime":"0","endTime":"0","summary":"DOGWOOD THERAPEUTICS INC宣布，公司预计在2026年年底前向美国食品药品监督管理局（FDA）提交Halneuron药物二期临床试验的总结报告。此次提交内容将全面涵盖该阶段的研究数据与分析结论。\n同时，公司还将呈报详细的生产工艺方案以及三期临床试验的整体开发规划。这一系列提交标志着Halneuron项目从中期研究向关键性临床试验阶段推进的重要里程碑。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DWTX","BK4139"],"gpt_icon":0},{"id":"1190589246","title":"DOGWOOD THERAPEUTICS INC 2026年展望：Halneuron推进至2B期开发阶段，最终数据预计于2026年第三季度公布","url":"https://stock-news.laohu8.com/highlight/detail?id=1190589246","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1190589246?lang=zh_cn&edition=full","pubTime":"2026-01-20 21:35","pubTimestamp":1768916152,"startTime":"0","endTime":"0","summary":"DOGWOOD THERAPEUTICS INC在2026年将继续推进其候选药物Halneuron的临床开发进程，目前该药物已进入关键的2B期临床试验阶段。公司计划稳步推进相关研究工作，最终的2B期临床试验数据预计将在2026年第三季度正式对外公布。这一重要时间节点的设定，标志着Halneuron研发项目取得了实质性进展，也为后续的临床开发路径奠定了坚实基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","DWTX"],"gpt_icon":0},{"id":"2603986607","title":"Dogwood Therapeutics, Inc.盘中异动 快速拉升5.22%","url":"https://stock-news.laohu8.com/highlight/detail?id=2603986607","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603986607?lang=zh_cn&edition=full","pubTime":"2026-01-15 04:43","pubTimestamp":1768423421,"startTime":"0","endTime":"0","summary":"北京时间2026年01月15日04时43分，Dogwood Therapeutics, Inc.股票出现波动，股价急速拉升5.22%。Dogwood Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.04%。其相关个股中，Alpha Tau Medical Ltd C/Wts 、Tango Therapeutics, Inc.、Sutro Biopharma, Inc.涨幅较大，Briacell Therapeutics Corp.、Clearmind Medicine Inc.、Nrx Pharmaceuticals, Inc.较为活跃，换手率分别为277.46%、82.38%、72.64%，振幅较大的相关个股有Alpha Tau Medical Ltd C/Wts 、Briacell Therapeutics Corp C/Wts 、Abpro Holdings Inc C/Wts 12/11/2029 ，振幅分别为56.54%、46.51%、41.18%。Dogwood Therapeutics, Inc.公司简介：Dogwood Therapeutics Inc前身为Virios Therapeutics Inc，是一家处于开发阶段的生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260115044342953ccc68&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260115044342953ccc68&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","BK4007","BK4139","DWTX","BK4539"],"gpt_icon":0},{"id":"1186306380","title":"Dogwood Therapeutics公司获2680万美元融资 推进Halneuron®二期B阶段研发","url":"https://stock-news.laohu8.com/highlight/detail?id=1186306380","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1186306380?lang=zh_cn&edition=full","pubTime":"2026-01-12 21:34","pubTimestamp":1768224864,"startTime":"0","endTime":"0","summary":"Dogwood Therapeutics公司近日宣布成功获得高达2680万美元的融资支持，该笔资金将专项用于推进其核心候选药物Halneuron®完成二期临床试验B阶段的研究工作。此次融资将为Halneuron®的临床开发计划提供关键资源保障，标志着该创新疗法在神经疾病治疗领域迈出重要一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1569","DWTX","00775","BK4139","BK1161"],"gpt_icon":0},{"id":"2592184118","title":"Dogwood Therapeutics, Inc.盘中异动 快速跳水5.32%","url":"https://stock-news.laohu8.com/highlight/detail?id=2592184118","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592184118?lang=zh_cn&edition=full","pubTime":"2025-12-19 04:07","pubTimestamp":1766088444,"startTime":"0","endTime":"0","summary":"北京时间2025年12月19日04时07分，Dogwood Therapeutics, Inc.股票出现波动，股价快速下跌5.32%。Dogwood Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.67%。其相关个股中，Protagenic Therapeutics Inc C/Wts 26/04/2026 、Athira Pharma, Inc.、Greenwich Lifesciences, Inc.涨幅较大，Athira Pharma, Inc.、Biodexa Pharmaceuticals Plc、Aditxt, Inc.较为活跃，换手率分别为1483.15%、291.20%、113.88%，振幅较大的相关个股有Protagenic Therapeutics Inc C/Wts 26/04/2026 、健永生技、Lexaria Bioscience Corp C/Wts 14/01/2026 ，振幅分别为65.12%、45.85%、44.39%。Dogwood Therapeutics, Inc.公司简介：Dogwood Therapeutics Inc前身为Virios Therapeutics Inc，是一家处于开发阶段的生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251219040724953b6d41&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251219040724953b6d41&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4539","LENZ","BK4007","DWTX"],"gpt_icon":0},{"id":"1113120173","title":"DOGWOOD THERAPEUTICS INC - 与Northland Securities签署股票分销协议 - SEC备案","url":"https://stock-news.laohu8.com/highlight/detail?id=1113120173","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1113120173?lang=zh_cn&edition=full","pubTime":"2025-11-29 03:20","pubTimestamp":1764357619,"startTime":"0","endTime":"0","summary":"DOGWOOD THERAPEUTICS INC - 与Northland Securities签署股票分销协议 - SEC备案","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DWTX","BK4139"],"gpt_icon":0},{"id":"1162666202","title":"Dogwood Therapeutics 第三季度每股收益USD -8.2","url":"https://stock-news.laohu8.com/highlight/detail?id=1162666202","media":"投资观察","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1162666202?lang=zh_cn&edition=full","pubTime":"2025-11-20 00:59","pubTimestamp":1763571598,"startTime":"0","endTime":"0","summary":"11月6日 - Dogwood Therapeutics 第三季度净收入为USD -1,570万美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DWTX","BK4139"],"gpt_icon":0},{"id":"1127799873","title":"Dogwood Therapeutics Inc通过全股票交易与Serpin Pharma达成协议，获得SP16免版税许可","url":"https://stock-news.laohu8.com/highlight/detail?id=1127799873","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1127799873?lang=zh_cn&edition=full","pubTime":"2025-09-29 19:17","pubTimestamp":1759144670,"startTime":"0","endTime":"0","summary":"Dogwood Therapeutics Inc宣布通过与Serpin Pharma的全股票交易，成功获得SP16项目的免版税许可权。此次交易将为Dogwood Therapeutics Inc在相关治疗领域的发展提供重要支持。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DWTX","BK4139"],"gpt_icon":0},{"id":"2570882552","title":"长江生命科技(00775)与DWTX订立弃权协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2570882552","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2570882552?lang=zh_cn&edition=full","pubTime":"2025-09-26 22:24","pubTimestamp":1758896694,"startTime":"0","endTime":"0","summary":"智通财经APP讯，长江生命科技 发布公告，诚如首份公告所披露，根据售股协议，向卖方发行买方普通股付款股份及买方Dogwood Therapeutics, Inc优先股付款股份乃作为向买方出售目标公司100%股权的代价，及买方优先股付款股份为卖方提供现金结算权及回购权。于2025年9月26日，卖方与买方订立弃权协议，双方同意就部分买方优先股付款股份放弃现金结算权及回购权。自首份公告及第二份公告以来，买方已公布 Halneuron 临床试验的进一步进展。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1350202.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1569","00775","BK4139","BK1161","DWTX"],"gpt_icon":0}],"profile":{"websiteUrl":"http://ir.dwtx.com","stockEarnings":[{"period":"1week","weight":-0.1042},{"period":"1month","weight":-0.0772},{"period":"3month","weight":-0.5723},{"period":"6month","weight":-0.4086},{"period":"1year","weight":-0.4869},{"period":"ytd","weight":-0.3389}],"compareEarnings":[{"period":"1week","weight":0.0009},{"period":"1month","weight":-0.0099},{"period":"3month","weight":0.0109},{"period":"6month","weight":0.0553},{"period":"1year","weight":0.1374},{"period":"ytd","weight":0.0007}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Dogwood Therapeutics, Inc.最初于2012年2月28日在阿拉巴马州成立，后来改为内华达州公司。该公司是一家处于发展阶段的生物技术公司，专注于推进新型抗病毒疗法，以治疗与病毒引发的异常免疫反应相关的疾病，如纤维肌痛（“FM”）。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.643793},{"month":2,"riseRate":0,"avgChangeRate":-0.159635},{"month":3,"riseRate":0.6,"avgChangeRate":0.055902},{"month":4,"riseRate":0.4,"avgChangeRate":0.172557},{"month":5,"riseRate":0.4,"avgChangeRate":0.163565},{"month":6,"riseRate":0.2,"avgChangeRate":-0.018729},{"month":7,"riseRate":0.6,"avgChangeRate":0.194525},{"month":8,"riseRate":0.4,"avgChangeRate":-0.123213},{"month":9,"riseRate":0.4,"avgChangeRate":-0.126251},{"month":10,"riseRate":0.2,"avgChangeRate":-0.193945},{"month":11,"riseRate":0.8,"avgChangeRate":-0.028445},{"month":12,"riseRate":0.4,"avgChangeRate":-0.112321}],"exchange":"NASDAQ","name":"DOGWOOD THERAPEUTICS INC","nameEN":"DOGWOOD THERAPEUTICS INC"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"DOGWOOD THERAPEUTICS INC(DWTX)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供DOGWOOD THERAPEUTICS INC(DWTX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"DOGWOOD THERAPEUTICS INC,DWTX,DOGWOOD THERAPEUTICS INC股票,DOGWOOD THERAPEUTICS INC股票老虎,DOGWOOD THERAPEUTICS INC股票老虎国际,DOGWOOD THERAPEUTICS INC行情,DOGWOOD THERAPEUTICS INC股票行情,DOGWOOD THERAPEUTICS INC股价,DOGWOOD THERAPEUTICS INC股市,DOGWOOD THERAPEUTICS INC股票价格,DOGWOOD THERAPEUTICS INC股票交易,DOGWOOD THERAPEUTICS INC股票购买,DOGWOOD THERAPEUTICS INC股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"DOGWOOD THERAPEUTICS INC(DWTX)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供DOGWOOD THERAPEUTICS INC(DWTX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}